Bracco Imaging Receives Regulatory Approval in China for SonoVue in the Assessment of Fallopian Tube Patency
New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced…
Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis onAugust 5, 2025
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi”…
EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline…
Cango Inc. Announces Results of Second Extraordinary General Meeting
HONG KONG, July 17, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango"…
Johnson & Johnson Launches VARIPULSE Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment
The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully…
Sirtex Medical’s SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the…
VivoPower Commences $29 Million Shareholder Loan Financing Retirement Plan
LONDON, July 07, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR)…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…